189 related articles for article (PubMed ID: 25820675)
1. Brain (18)F-DOPA PET and cognition in de novo Parkinson's disease.
Picco A; Morbelli S; Piccardo A; Arnaldi D; Girtler N; Brugnolo A; Bossert I; Marinelli L; Castaldi A; De Carli F; Campus C; Abbruzzese G; Nobili F
Eur J Nucl Med Mol Imaging; 2015 Jun; 42(7):1062-70. PubMed ID: 25820675
[TBL] [Abstract][Full Text] [Related]
2. Cortical 6-[18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson's disease.
Brück A; Aalto S; Nurmi E; Bergman J; Rinne JO
Neurobiol Aging; 2005 Jun; 26(6):891-8. PubMed ID: 15718048
[TBL] [Abstract][Full Text] [Related]
3. Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson's disease.
Cheesman AL; Barker RA; Lewis SJ; Robbins TW; Owen AM; Brooks DJ
J Neurol Neurosurg Psychiatry; 2005 Sep; 76(9):1204-10. PubMed ID: 16107352
[TBL] [Abstract][Full Text] [Related]
4. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study.
Rakshi JS; Uema T; Ito K; Bailey DL; Morrish PK; Ashburner J; Dagher A; Jenkins IH; Friston KJ; Brooks DJ
Brain; 1999 Sep; 122 ( Pt 9)():1637-50. PubMed ID: 10468504
[TBL] [Abstract][Full Text] [Related]
5. [Clinical utility of (18)F-DOPA-PET in movement disorders. A systematic review].
Puñal-Riobóo J; Serena-Puig A; Varela-Lema L; Alvarez-Páez AM; Ruano-Ravina A
Rev Esp Med Nucl; 2009; 28(3):106-13. PubMed ID: 19558950
[TBL] [Abstract][Full Text] [Related]
6. Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study.
Brück A; Aalto S; Nurmi E; Vahlberg T; Bergman J; Rinne JO
Mov Disord; 2006 Jul; 21(7):958-63. PubMed ID: 16550545
[TBL] [Abstract][Full Text] [Related]
7. Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease.
Eshuis SA; Maguire RP; Leenders KL; Jonkman S; Jager PL
Eur J Nucl Med Mol Imaging; 2006 Feb; 33(2):200-9. PubMed ID: 16228235
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of dopaminergic presynaptic function by [F-18] DOPA PET].
Kato T
Rinsho Shinkeigaku; 2007 Nov; 47(11):829-31. PubMed ID: 18210809
[TBL] [Abstract][Full Text] [Related]
9. Relation of 18-F-Dopa PET with hypokinesia-rigidity, tremor and freezing in Parkinson's disease.
Pikstra ARA; van der Hoorn A; Leenders KL; de Jong BM
Neuroimage Clin; 2016; 11():68-72. PubMed ID: 26909330
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of 6-11C-Methyl-m-Tyrosine as a PET Probe for Presynaptic Dopaminergic Activity: A Comparison PET Study with β-11C-l-DOPA and 18F-FDOPA in Parkinson Disease Monkeys.
Kanazawa M; Ohba H; Harada N; Kakiuchi T; Muramatsu S; Tsukada H
J Nucl Med; 2016 Feb; 57(2):303-8. PubMed ID: 26564319
[TBL] [Abstract][Full Text] [Related]
11. Current status and future challenges of brain imaging with (18)F-DOPA PET for movement disorders.
Calabria FF; Calabria E; Gangemi V; Cascini GL
Hell J Nucl Med; 2016; 19(1):33-41. PubMed ID: 26929938
[TBL] [Abstract][Full Text] [Related]
12. Cognitive- and motor-related regions in Parkinson's disease: FDOPA and FDG PET studies.
Nagano-Saito A; Kato T; Arahata Y; Washimi Y; Nakamura A; Abe Y; Yamada T; Iwai K; Hatano K; Kawasumi Y; Kachi T; Dagher A; Ito K
Neuroimage; 2004 Jun; 22(2):553-61. PubMed ID: 15193583
[TBL] [Abstract][Full Text] [Related]
13. Monosymptomatic resting tremor and Parkinson's disease: a multitracer positron emission tomographic study.
Ghaemi M; Raethjen J; Hilker R; Rudolf J; Sobesky J; Deuschl G; Heiss WD
Mov Disord; 2002 Jul; 17(4):782-8. PubMed ID: 12210876
[TBL] [Abstract][Full Text] [Related]
14. Corticostriatal covariance patterns of 6-[18F]fluoro-L-dopa and [18F]fluorodeoxyglucose PET in Parkinson's disease.
Kaasinen V; Maguire RP; Hundemer HP; Leenders KL
J Neurol; 2006 Mar; 253(3):340-8. PubMed ID: 16222426
[TBL] [Abstract][Full Text] [Related]
15. The role of exposure to pesticides in the etiology of Parkinson's disease: a
Djaldetti R; Steinmetz A; Rigbi A; Scherfler C; Poewe W; Roditi Y; Greenbaum L; Lorberboym M
J Neural Transm (Vienna); 2019 Feb; 126(2):159-166. PubMed ID: 30426251
[TBL] [Abstract][Full Text] [Related]
16. Anterior cingulate dopamine turnover and behavior change in Parkinson's disease.
Gallagher CL; Bell B; Palotti M; Oh J; Christian BT; Okonkwo O; Sojkova J; Buyan-Dent L; Nickles RJ; Harding SJ; Stone CK; Johnson SC; Holden JE
Brain Imaging Behav; 2015 Dec; 9(4):821-7. PubMed ID: 25511521
[TBL] [Abstract][Full Text] [Related]
17. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study.
Rinne JO; Portin R; Ruottinen H; Nurmi E; Bergman J; Haaparanta M; Solin O
Arch Neurol; 2000 Apr; 57(4):470-5. PubMed ID: 10768619
[TBL] [Abstract][Full Text] [Related]
18. Cognitive-nigrostriatal relationships in de novo, drug-naïve Parkinson's disease patients: a [I-123]FP-CIT SPECT study.
Nobili F; Campus C; Arnaldi D; De Carli F; Cabassi G; Brugnolo A; Dessi B; Morbelli S; Sambuceti G; Abbruzzese G; Rodriguez G
Mov Disord; 2010 Jan; 25(1):35-43. PubMed ID: 20058228
[TBL] [Abstract][Full Text] [Related]
19. Frontal FDG-PET activity correlates with cognitive outcome after STN-DBS in Parkinson disease.
Kalbe E; Voges J; Weber T; Haarer M; Baudrexel S; Klein JC; Kessler J; Sturm V; Heiss WD; Hilker R
Neurology; 2009 Jan; 72(1):42-9. PubMed ID: 19122029
[TBL] [Abstract][Full Text] [Related]
20. Discordant twins with Parkinson's disease: positron emission tomography and early signs of impaired cognitive circuits.
Holthoff VA; Vieregge P; Kessler J; Pietrzyk U; Herholz K; Bönner J; Wagner R; Wienhard K; Pawlik G; Heiss WD
Ann Neurol; 1994 Aug; 36(2):176-82. PubMed ID: 8053653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
